Achaogen competitors

Robert B. Ford is an American businessman and the thirteenth chief executive officer at Abbott Laboratories, a publicly-traded medical devices and health care company based in Abbott Park, Illinois. He received a bachelor's degree from Boston College and an MBA in business administration from the University of California, Berkeley, Haas School of Business.

Mike Raab has been Chief Executive Officer and Chairman of Ardelyx since March 2009. Before Ardelyx, Mike was a partner at New Enterprise Associates (NEA) one of the world’s largest and most successful venture capital firms and specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors. Prior to joining NEA in 2002, Mike spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation. He built the Latin American division for Genzyme and was also Senior Product Manager for Genzyme’s $1+ billion therapies for Gaucher Disease, Ceredase and Cerezyme, and was instrumental in the worldwide launch of both products. Mike also spent two years with Genzyme’s Diagnostic products and services division. Previous to Genzyme, Mike held business development and sales and marketing positions at Repligen and Bristol-Myers. Mike received his B.A. from DePauw University.

Evan Loh works at PARATEK PHARMACEUTICALS, INC. and a President, COO & CMO at PARATEK PHARMACEUTICALS, INC. and is based in Merion Station, Pennsylvania.

Jonathan Steckbeck is a Founder President CEO at Peptilogics and Director at Peptilogics and is based in Pittsburgh, Pennsylvania. He attended Penn State University, Katz Graduate School of Business, and University of Pittsburgh School of Medicine.

CEO of Spero Therapeutics, a public, clinical stage company developing a pipeline of therapeutics treating large unmet needs in infectious disease. Co-founder of nine biotech startups developing novel platforms and therapies, including Spero Therapeutics (Nasdaq:SPRO), Synlogic (Nasdaq: SYBX), and Arteaus Therapeutics (Acquired by Eli Lilly, Emgality FDA approved by Eli Lilly). Advisor at Atlas Venture, an early stage life sciences and technology venture capital firm. Some more on my perspective at http://lifescivc.com/2014/04/building-great-startup-teams-in-biotech-a-three-hour-tour, http://lifescivc.com/2014/07/growing-beyond-the-startup-phase-lessons-learned, and at https://timmermanreport.com/2018/08/zigging-when-others-zag-speros-ankit-mahadevia-on-the-antibiotic-opportunity.

Corey N. Fishman has served as our Chief Operating Officer since August 2010 and as our Chief Financial Officer since June 2012. From 2008 to 2010, Mr. Fishman served as Chief Financial Officer of GANIC Pharmaceuticals, Inc. From 2006 to 2008, he served as Chief Financial Officer of MedPointe Inc. until its acquisition by Meda AB. Mr. Fishman holds a B.A. in Economics from the University of Illinois at Urbana-Champaign and an M.S.M. in Finance from the Krannert School of Management at Purdue University.